EP3980123B1 - An 2,5-diformylfuran reiches moringa-peregrina-samenextrakt, verfahren zu seiner herstellung und seine verwendung bei kosmetischen zusammensetzungen - Google Patents
An 2,5-diformylfuran reiches moringa-peregrina-samenextrakt, verfahren zu seiner herstellung und seine verwendung bei kosmetischen zusammensetzungen Download PDFInfo
- Publication number
- EP3980123B1 EP3980123B1 EP21728208.6A EP21728208A EP3980123B1 EP 3980123 B1 EP3980123 B1 EP 3980123B1 EP 21728208 A EP21728208 A EP 21728208A EP 3980123 B1 EP3980123 B1 EP 3980123B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- peregrina
- moringa
- test
- seeds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 226
- 241000339422 Moringa peregrina Species 0.000 title claims description 87
- 239000000203 mixture Substances 0.000 title claims description 61
- PXJJKVNIMAZHCB-UHFFFAOYSA-N 2,5-diformylfuran Chemical compound O=CC1=CC=C(C=O)O1 PXJJKVNIMAZHCB-UHFFFAOYSA-N 0.000 title claims description 28
- 239000002537 cosmetic Substances 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 27
- 230000008569 process Effects 0.000 title claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 239000002904 solvent Substances 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 230000032683 aging Effects 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000007790 solid phase Substances 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 239000006184 cosolvent Substances 0.000 claims description 7
- 239000007791 liquid phase Substances 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 238000000956 solid--liquid extraction Methods 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000002040 relaxant effect Effects 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 238000001728 nano-filtration Methods 0.000 claims description 2
- 239000011368 organic material Substances 0.000 claims description 2
- 230000008845 photoaging Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims 1
- 239000011343 solid material Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 105
- 230000000694 effects Effects 0.000 description 93
- 241001300668 Jatropha integerrima Species 0.000 description 88
- 239000000047 product Substances 0.000 description 65
- 230000005764 inhibitory process Effects 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 42
- 102000004190 Enzymes Human genes 0.000 description 40
- 108090000790 Enzymes Proteins 0.000 description 40
- 229940088598 enzyme Drugs 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 37
- 238000011534 incubation Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 35
- 239000000758 substrate Substances 0.000 description 33
- 230000004913 activation Effects 0.000 description 31
- 102000029816 Collagenase Human genes 0.000 description 28
- 108060005980 Collagenase Proteins 0.000 description 28
- 108010003272 Hyaluronate lyase Proteins 0.000 description 26
- 238000002835 absorbance Methods 0.000 description 26
- 244000179886 Moringa oleifera Species 0.000 description 25
- 229960002424 collagenase Drugs 0.000 description 25
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 24
- 238000000605 extraction Methods 0.000 description 23
- 235000011347 Moringa oleifera Nutrition 0.000 description 22
- 102000001974 Hyaluronidases Human genes 0.000 description 21
- 108010017842 Telomerase Proteins 0.000 description 21
- 229960002773 hyaluronidase Drugs 0.000 description 21
- 239000003921 oil Substances 0.000 description 19
- 241001640023 Janusia Species 0.000 description 18
- 108010058864 Phospholipases A2 Proteins 0.000 description 18
- 102100026918 Phospholipase A2 Human genes 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 230000035899 viability Effects 0.000 description 17
- 102000003425 Tyrosinase Human genes 0.000 description 16
- 108060008724 Tyrosinase Proteins 0.000 description 16
- 102000011990 Sirtuin Human genes 0.000 description 14
- 108050002485 Sirtuin Proteins 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 13
- -1 carbohydrate compound Chemical class 0.000 description 13
- 239000001963 growth medium Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 12
- 102100033902 Endothelin-1 Human genes 0.000 description 12
- 239000008272 agar Substances 0.000 description 12
- 230000002503 metabolic effect Effects 0.000 description 12
- 101800004490 Endothelin-1 Proteins 0.000 description 11
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 102000005741 Metalloproteases Human genes 0.000 description 9
- 108010006035 Metalloproteases Proteins 0.000 description 9
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 101000805943 Homo sapiens Usher syndrome type-1G protein Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 102100037929 Usher syndrome type-1G protein Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000003712 anti-aging effect Effects 0.000 description 8
- 230000002180 anti-stress Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010015150 Erythema Diseases 0.000 description 7
- 101710096328 Phospholipase A2 Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000012429 reaction media Substances 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000008366 buffered solution Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- LFFIJRJGKBSELO-FQEVSTJZSA-O diheptanoyl sn-dithiophosphatidylcholine Chemical compound CCCCCCC(=O)SC[C@H](COP(O)(=O)OCC[N+](C)(C)C)SC(=O)CCCCCC LFFIJRJGKBSELO-FQEVSTJZSA-O 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000002085 irritant Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 5
- 108050009340 Endothelin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010874 in vitro model Methods 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 231100000065 noncytotoxic Toxicity 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- WLWWVTPUDQTUJU-KDXMTYKHSA-O 2-[[(2s)-2-(hexadecanoylamino)-3-hexadecylsulfanylpropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCCSC[C@H](COP(O)(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCCCC WLWWVTPUDQTUJU-KDXMTYKHSA-O 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- 241000220214 Moringaceae Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000850 deacetylating effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000023753 dehiscence Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Natural products CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 2
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000519852 Brachychiton populneus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000218980 Brassicales Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100119767 Caenorhabditis elegans fat-4 gene Proteins 0.000 description 1
- 101100468762 Caenorhabditis elegans ric-3 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 240000002228 Cynara humilis Species 0.000 description 1
- 235000005921 Cynara humilis Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019030 Hair colour changes Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 231100000107 OECD 471 Bacterial Reverse Mutation Test Toxicity 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- DUFKCOQISQKSAV-UHFFFAOYSA-N Polypropylene glycol (m w 1,200-3,000) Chemical class CC(O)COC(C)CO DUFKCOQISQKSAV-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XLSMFKSTNGKWQX-UHFFFAOYSA-N alpha-hydroxyacetone Natural products CC(=O)CO XLSMFKSTNGKWQX-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000001390 anti-relaxing effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000003239 corneal fibroblast Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- URPBIQPJABGDJD-UHFFFAOYSA-N methyl 7-oxodehydroabietate Natural products CC(C)C1=CC=C2C3(C)CCCC(C(=O)OC)(C)C3CC(=O)C2=C1 URPBIQPJABGDJD-UHFFFAOYSA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100001183 nonphototoxic Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 231100001254 ocular irritant Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 231100000119 phototoxicity / photoirritation testing Toxicity 0.000 description 1
- 229910052615 phyllosilicate Inorganic materials 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000003408 pro-mutagenic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013468 resource allocation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003542 rubefacient Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940080272 sodium coco-sulfate Drugs 0.000 description 1
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229910000648 terne Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
Definitions
- the invention relates to the field of cosmetics and nutricosmetics and more particularly that of the active ingredients used in the formulation of compositions for skin care.
- the invention relates to an extract of the seeds of Moringa peregrina rich in the compound 2,5-diformylfuran (DFF).
- DFF 2,5-diformylfuran
- the invention also relates to the process for obtaining a particular extract from the seeds of Moringa peregrina, the cosmetic compositions comprising such extracts, and finally the cosmetic or nutricosmetic use of such compositions for the care of the skin, the scalp and appendages.
- the Moringaceae constitute a mono-generic family (a single genus, Moringa Adans), an element of the Saharo-Sindian flora, made up of between twelve and fourteen species according to the authors, distributed from East Africa to Asia.
- the genus is classically divided into 3 sections which are, however, not confirmed as mono-phyletic by phylogenetic analyses. The latter have instead highlighted clades focused on certain morphological characters: pachycaules (“bottle trees”); tuberous (“tuberous trees”) and neither pachycaules - nor tuberous (“slender trees”).
- the species Moringa peregrina (Forssk.) Fiori belongs to the third group.
- Moringa peregrina occupies compared to other species of its clade the most arid and inhospitable habitats. It is apparently more drought resistant than Moringa oleifera which is planted commercially on a large scale in tropical and subtropical areas.
- Moringa peregrina oil was actively traded in early Islam in the AlUla region (NASEF, AAS, 1995, Al-'Ula, A study of Cultural and Social Heritage ).
- the oil produced locally from Moringa peregrina is now mainly intended for self-consumption or local markets.
- Extracts from the seed of Moringa oleifera are known in the cosmetic field.
- oil including triglycerides, fatty acids and polar lipids
- polyphenols and its use in cosmetic compositions for combating skin ageing.
- it is the apolar part of the seed of Moringa oleifera which appears to be active, and more particularly the oily part.
- Moringa peregrina species certain phenolic compounds and flavonoids obtained from the leaves or the whole seed of Moringa peregrina are known to exhibit antioxidant activity ( AL-DABBAS M., 2017, Antioxidant activity of different extracts from the aerial part of Moringa peregrina (Forssk.) Fiori, from Jordan, Pakistan Journal of Pharmaceutical Sciences, 30(6): 2151-2157 ). These compounds are extracted with solvents such as methanol, ethyl acetate or hexane from the leaves or whole seeds. It appears that the leaves contain the most active compounds.
- the composition of the extract conditions the biological activity and consequently the cosmetic efficacy.
- a problem which the invention proposes to solve is to develop new products based on an extract of the species M. peregrina of the genus Moringa which can be used in cosmetics and are easy to implement.
- the Applicant has demonstrated a new extract obtained from the seeds and more specifically from the cake of the seeds of the species Moringa peregrina, which has in particular a relaxing and anti-stress activity for the skin, an anti- aging as well as a preventive activity against age spots.
- the extract according to the invention is rich in 2,5-diformylfuran (DFF), a compound also called 2,5-furandicarboxaldehyde.
- DFF 2,5-diformylfuran
- the extract is obtained specifically from the seeds or more specifically from the cake of the unshelled seeds of Moringa peregrina, in particular by an alcoholic extraction.
- the extract according to the invention is new for two reasons in the field of cosmetics compared to the extracts of the prior art, on the one hand by the specific species of origin used and on the other hand by its content in particular compounds.
- the first subject of the invention is an extract of the seeds of Moringa peregrina rich in the compound 2,5-diformylfuran.
- the compound 2,5-diformylfuran is a rare carbohydrate compound in the plant kingdom and synthesized from furfural via the intermediate synthesis of 5-hydroxymethylfurfural.
- the extract according to the invention is unique in the Moringa genus. It will be demonstrated that the Moringa peregrina species has a particular molecular profile different from those known of the other species of the genus, in particular of the Moringa oleifera species, which the Applicant has been able to demonstrate.
- a third subject of the invention is a cosmetic or nutricosmetic composition
- a cosmetic or nutricosmetic composition comprising, as active agent, an effective amount of a Moringa peregrina seed extract according to the invention and a physiologically acceptable excipient.
- a fourth subject of the invention is the cosmetic or nutricosmetic use of a composition according to the invention, to improve the appearance of the skin, mucous membranes or appendages, to relax, soothe and de-stress the skin and to prevent and/ or fight against the cutaneous signs of aging and/or photo-ageing, to prevent age spots.
- the invention relates firstly to an extract of Moringa peregrina seeds rich in the 2,5-diformylfuran compound.
- the 2,5-diformylfuran molecule also called 2,5-furandicarboxaldehyde, has never been characterized in an extract from the seeds of Moringa species.
- the Moringa peregrina species grows in very arid climates. Thus, its ability to resist drought has enabled it to acquire unique special characteristics, which the Applicant has been able to identify by implementing an extraction process adapted to whole seeds or preferentially to seed cake. .
- the plant part chosen is the seed of Moringa peregrina. It is known that the seeds of Moringa peregrina are used for the extraction of their oil called peregrina oil (INCI name "Moringa peregrina seed oil”), used regionally for self-consumption or in various traditional medicinal indications.
- peregrina oil ICI name "Moringa peregrina seed oil”
- the cake obtained after the seed has been de-oiled is a waste currently used for animal feed in particular.
- the extract of Moringa peregrina is obtained by solid-liquid extraction of the cake from the unshelled seeds, with stirring, in a proportion of approximately 25% by weight of solid matter relative to the total weight.
- the alcohol being chosen from ethanol or methanol optionally with a co-solvent of the polyol or subcritical water type, in a proportion of 70 to 100% by weight of alcohol relative to the total weight of the solvent, at a temperature of between 16 and 30°C for a period of approximately 2 hours, and by separation of the liquid and solid phases so as to eliminate the solid phase and recover a liquid extract of Moringa peregrina seed, said extract being rich in 2,5-diformylfuran compound.
- the extract according to the invention is obtained from the cake of the seeds harvested at maturity from the fruit of Moringa peregrina after extraction of the peregrina oil (INCI name “Moringa peregrina seed oil”).
- the active principle of the extract according to the invention namely 2,5-diformylfuran, is a molecule of mixed polarity exhibiting a certain fragility.
- the extract obtained from the whole unshelled seed will have to be selectively extracted to obtain a high concentration of active ingredients, using the appropriate solvents and co-solvents and a temperature not exceeding 30°. vs.
- the co-solvents can be, for example, glycol ethers (mono- or di-propylene glycol, propanediol, and other propylene glycol derivatives, ethylene or diethylene glycol derivatives), glycerol, dimethyl ether isosorbide, methyl or ethyl or propyl esters of fatty acids; dicraprylyl carbonate, dicaprylyl ether, alkyl acetate or propionate, acetone, methyl or ethyl ketone, monoterpenes such as alpha-pinene or limonene.
- the proportions of these co-solvents can be mixed with the primary solvent (eg ethanol or methanol) from 0 to 30% (V/V).
- the extraction conditions can be under atmospheric pressure or under vacuum or under an inert atmosphere, but preferably in the dark at a temperature between 16 and 30°C.
- the extract is obtained from the cake of the unshelled seeds by solid-liquid extraction, with an alcoholic solvent 96° ethanol.
- the liquid extract obtained is dried so as to obtain a dry extract of Moringa peregrina seed cake containing more than 50% by weight of 2,5-diformylfuran relative to the total weight of the material dried.
- the dry extract of Moringa peregrina seed cake contains more precisely about 55% by weight of 2,5-diformylfuran, 2.5% of furfural, 1.2% of isopropyl myristate, 4.7% of palmitic acid, 11.1% of oleic acid and 25.8% triglycerides relative to the total weight of dry matter.
- the unshelled seeds are collected, ie the shell of which is kept, when the fruit matures and preferably when the pod is at the start of dehiscence.
- the seeds are dried to obtain a rate internal humidity around 6%, drying will preferably be done on a ventilated shelf sheltered from the sun's rays, preferably under a shadehouse in the open air.
- the dried seeds are then ground extemporaneously by cold pressing, which makes it possible to mechanically separate the peregrina oil (INCI name “Moringa peregrina seed oil”) from the rest of the compressed seed, namely the cake.
- the cake is then crushed mechanically with any type of mechanical crusher such as a hammer, flail, knife or crushing/shredding system.
- any type of mechanical crusher such as a hammer, flail, knife or crushing/shredding system.
- the extraction is advantageously always carried out with stirring, thus allowing dispersion and homogenization of the solid in the liquid, improving the diffusion of the solute in the solvent.
- an alcoholic solvent of 96° ethanol type will be preferred, but methanol can also be used, with a co-solvent of polyol type or subcritical water.
- the vegetable matter, residual and depleted in the compound of interest is advantageously separated from the liquid phase by clarifying filtration. Even more preferably, the solvent is 96° ethanol.
- a liquid extract will advantageously be obtained from the cake of Moringa peregrina seeds comprising between 0.5% and 1.6% of dry matter, this dry matter being composed of at least 50% of 2,5-diformylfuran which corresponds approximately between 0.25% and 0.8% by weight of the total weight of the liquid extract.
- the liquid Moringa peregrina extract obtained is purified by distillation, microfiltration, ultrafiltration and/or nanofiltration to concentrate the extract in the 2,5-diformylfuran compound of interest relative to the organic materials also extracted, in particular to the rest of the extracted material such as fatty substances and derivatives also extracted.
- These purification steps make it possible to concentrate the compound of interest at the expense of other compounds extracted as mentioned, as well as of the solvent.
- the liquid extract obtained is dried so as to obtain a dry extract of the cake of Moringa peregrina seeds containing more than 50% by weight of compound 2,5- diformylfuran of interest relative to the total weight of dry matter extracted.
- the liquid Moringa peregrina seed extract obtained is preferably dried, for example by atomization, freeze-drying or zeodration so as to obtain an extract of seed cake of solid Moringa peregrina , the ethanol being evaporated.
- the drying can be carried out in the presence of an organic support such as maltodextrin, cyclodextrin or inulin, or in the presence of an inorganic support such as phyllosilicate, magnesium silicate or carbonate and its salts.
- the invention also relates to the extract of the seeds of Moringa peregrina capable of being obtained by the process for obtaining according to the invention.
- a third subject of the invention is a cosmetic or nutracosmetic composition
- a cosmetic or nutracosmetic composition comprising, as active agent, an effective amount of an extract of seeds of Moringa peregrina according to the invention, and a physiologically acceptable excipient.
- composition according to the invention can be formulated in the form of various preparations suitable for topical administration or for oral administration.
- the various preparations are suitable for topical administration and include creams, oil-in-water and water-in-oil emulsions, milks, ointments, lotions, oils, balms, aqueous or hydro - alcoholic or glycolic, serums, powders, patches, sprays or any other product for external application such as, for example, medical devices or cosmetic-textile products.
- the different preparations are suitable for oral administration; the plant extract comprising the active compound 2,5-diformulfuran being able to enter either into a food composition or into a food supplement.
- the food supplement may be in the form of capsules or soft gelatin or vegetable capsules within the scope of the present invention.
- Said food supplement can then contain from 0.01 to 100% by weight of the plant extract. More preferably, the amount of plant extract is from 0.02 to 40% by weight, and in particular from 0.2 to 20% by weight relative to the total weight of the composition.
- composition will advantageously be formulated in the form of a preparation suitable for oral administration. It may not comprise any excipient and may consist entirely of the plant extract comprising the active compound 2,5-diformylfuran.
- compositions according to the invention are intended more particularly for topical administration.
- These compositions must therefore contain a cosmetically acceptable medium, that is to say compatible with the skin and the superficial body growths, and cover all cosmetic forms.
- These compositions may in particular be in the form of creams, oil-in-water or water-in-oil emulsions or multiple emulsions, serums, solutions, suspensions, gels, milks, lotions, sticks or even powders, and suitable for application on the skin, lips and/or appendages.
- compositions include the excipients necessary for their formulation, such as solvents, emollients, thickeners, diluents, surfactants, antioxidants, bioactive agents, dyes, preservatives, fragrances. They can be used as a care product and/or as a make-up product for the skin.
- the composition according to the invention may in particular consist of a composition for hair care, and in particular a shampoo, a conditioner, a treatment lotion, a styling cream or gel, a restructuring lotion for the hair, a mask, etc.
- the cosmetic composition according to the invention can be used in particular in treatments implementing an application which may or may not be followed by rinsing, or else in the form of a shampoo.
- the composition according to the invention can advantageously be used in anti-dandruff care. It may also be in the form of a dye or a mascara to be applied with a brush or a comb, in particular on the eyelashes, the eyebrows or the hair.
- compositions according to the invention further comprise any additive commonly used in the field of application envisaged as well as the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, colorants, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
- any additive commonly used in the field of application envisaged as well as the adjuvants necessary for their formulation such as solvents, thickeners, diluents, antioxidants, colorants, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
- the quantity or content of plant extract in the composition according to the invention is from 0.002 to 20% by weight, and in particular from 0.001 to 10% by weight relative to the total weight of the composition.
- the fourth object of the invention is the cosmetic or nutricosmetic use of a composition according to the invention for improving the appearance of the skin, mucous membranes and appendages, for relaxing, soothing and de-stressing the skin and preventing and/or or to fight against the cutaneous signs of aging and/or photo-aging and prevent age spots.
- the purpose of the use according to the invention is more particularly to relax, soothe and de-stress the skin and to combat the signs of skin ageing.
- the purpose of the use according to the invention is to avoid the appearance of age spots.
- Example 1 Preparation of a plant extract from Moringa peregrina cake
- Unshelled seeds harvested at maturity from the fruit of Moringa peregrina (Forssk.) Fiori were dried to obtain an internal humidity level of less than 8% and preferably around 6%, then pressed with a mechanical screw press. , so as to separate the oil from the rest of the seed to obtain virgin oil on the one hand and cake on the other. The cake is then isolated in the form of sausages pre-cut into 1 to 2 cm pieces.
- This peregrina extract according to the invention contains 1.15% of dry matter comprising itself (results expressed in relation to the dry matter (DM): [Tables1] Active compounds MS total compounds % Furfural 2.528 57.18 2,5-Furandicarboxaldehyde 54.66 Fats of plant origin Isopropyl myristate 1.175 42.812 palmitic acid 4.713 Oleic acid 11.093 Trigycerides 25.831
- the dry extract described above is obtained by a gravimetric method based on the mass before and after evaporation present in the liquid extract.
- the objective of this study is to evaluate the modulation of the antioxidant activity by the peregrina extract in an acellular in vitro colorimetric model using the radical DPPH (2,2-diphenyl-1-picrylhydrazyl) as well as to the reference antioxidant, ascorbic acid.
- the method used is called inhibition. It is based on the degradation of the oxidizing radical DPPH, with a violet color absorbing at 540 nm, by a reference antioxidant, ascorbic acid. This reaction serves as a positive control and leads to the formation of the DPPH compound which is colorless or even light yellow.
- the peregrina extract according to the invention and the “Ascorbic Acid” reference product are brought into contact with the DPPH solution for 30 min at 40°C.
- the antioxidant activity is then evaluated by measuring absorbance at 540 nm.
- the modulation of this activity is expressed as a percentage of stimulation of the antioxidant activity by the active ingredient tested, with the maximum antioxidant activity obtained in the presence of ascorbic acid (T+) as a reference.
- the peregrina extract according to the invention is capable of protecting against free radicals, it has significant antioxidant properties from a concentration of 1%.
- the objective of this study is to evaluate the modulation of the inhibitory activity of metalloproteases by the peregrina extract according to the invention in an acellular in vitro model using a type I collagenase and a hyaluronidase, a complex of substrate and a chromophore, Ninhydrin.
- a buffered solution of collagenase type I and hyaluronidase reacts with a specific substrate complex and converts it to form a compound capable of activating a chromophore by incubation at 80°C for 15 min.
- the activity of collagenase and hyaluronidase can thus be evaluated by measuring absorbance at 565 nm.
- the sample is brought into contact with the solution of collagenase and hyaluronidase at the same time as the substrate complex of the enzymes at 37° C. for 5 minutes.
- the substrate transformed by the enzymes is capable of activating the chromophore by incubation at 80° C. for 15 minutes.
- the collagenase and hyaluronidase activity in the presence/absence of the sample is then evaluated by measuring the absorbance at 565 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the activity of collagenase and hyaluronidase in the absence of active ingredient, that is to say only in the presence of the substrate of the enzyme.
- a solution of type I collagenase and hyaluronidase enzymes is incubated in its substrate, for 5 minutes, in the absence or presence of the peregrina extract according to the invention tested.
- the solutions are then brought into contact with the chromogen, Ninhydrin, before incubation for 15 minutes at 80°C.
- the activity of the collagenase and hyaluronidase enzymes with and without test or reference product was evaluated by measuring the absorbance of the reaction media at 565 nm. For each concentration tested, the modulation of the activity of the enzymes collagenase and hyaluronidase by the product under test is calculated according to the following formula.
- Percentage of modulation of I ′ activity of the enzyme collagenase/hyaluronidase 100 ⁇ DO product To I ′ essay Or of reference ⁇ DO collagenase/hyaluronidase only / DO collagenase / hyaluronidase only .
- the peregrina extract according to the invention generates a strong inhibition of metalloproteases (collagenase/hyaluronidase) of 62% at very low levels of 0.01%.
- the peregrina extract according to the invention is capable of strongly inhibiting these metalloproteases and has good potential for protecting the extracellular matrix of the skin with great effectiveness and, through this inhibition, it shows an anti-aging effect.
- the objective of this study is to demonstrate the inhibitory activity of the peregrina extract according to the invention on the HDACs and Sirtuins I enzymes.
- a buffered solution of HDACs & Sirtuins I reacts with a substrate for 20 minutes at 37°C and transforms it to form a compound which is colored in the presence of a developer after incubation at 37° C. for 10 minutes.
- the maximum deacetylation activity of Sirtuins can thus be evaluated by measuring the absorbance at 405 nm.
- the peregrina extract according to the invention or the reference product “Trichostatin A (STA) inhibitor 1 ⁇ M” are brought into contact with the solution of Sirtuins at the same time as the substrate of the enzyme for 20 minutes at 37° C., the substrate transformed by the enzyme is colored by the addition of a developer.
- the deacetylating activity of HDACs and Sirtuin I in the presence of the active ingredient is then evaluated by measuring the absorbance at 405 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the maximum activity of HDACs & Sirtuin I in the absence of active ingredient, that is to say only in the presence of the substrate of HDACs & Sirtuin I enzymes. .
- a solution of Sirtuins enzymes is incubated in its substrate for 20 min in the absence (control) or presence of the reference product, or of increasing concentrations of the products under test.
- the peregrina extract according to the invention is tested at the following concentrations: 2%; 1%; 0.1% (V/V).
- the activity of the Sirtuins enzymes with and without test or reference product was revealed by staining using a developer solution (10 min at 37°C) and evaluated by measuring the absorbance of the reaction media at 405 nm.
- the modulation of the deacetylating activity of the enzymes Histones Deacetysases and Sirtuins I by the product under test is calculated according to the following formula.
- HDACs Histone Desacetylases
- the peregrina extract according to the invention shows a significant inhibition of HDACs; this inhibition means the ability to promote the self-protection of skin cells against genetic drift, especially related to the aging process.
- the extract appears to be useful against one of the most common genetic drifts on the surface of the skin, namely fibrosis which is manifested by the appearance of a "pimple" of flesh (fibrotic protuberance).
- the extract may advantageously interfere with the phenomena of fibrosis at the surface of the skin and thus prevent the aging of the skin.
- the objective of this study is to evaluate the modulation of the anti-inflammatory activity of the enzyme phospholipase A2 by one or more samples in an acellular In Vitro model using the "SPLA2 (type V) Inhibitor" analysis kit. Screening Assay Kit”.
- Phospholipase A2 is a key enzyme upstream of the inflammatory process triggered by the arachidonic cascade.
- a buffered solution of Phospholipase A2 reacts with a specific substrate, diheptanoyl thio-PC, and converts it to form a compound which binds to a chromogen, DTNB under stirring at room temperature.
- the activity of phospholipase A2 can thus be evaluated by measuring the absorbance at 413 nm.
- the peregrina extract according to the invention or the inhibitor reference product “Thioetheramide-PC” are brought into contact with the solution of Phospholipase A2 at the same time as the substrate of the enzyme.
- the substrate transformed by the enzyme is stained using the chromogen DTNB by stirring at room temperature.
- the activity of the peregrina extract according to the invention or of the reference product is then evaluated by measuring the absorbance at 413 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the activity of Phospholipase A2 in the absence of active ingredient, that is to say only in the presence of the substrate of the enzyme (diheptanoyl thio- pc).
- a solution of Phospholipase A2 enzyme is incubated in its substrate, diheptanoyl thio-PC, in the absence or presence of the reference inhibitor and of the peregrina extract according to the invention, tested at the following concentrations: 2%; 1%; 0.1% (V/V), then the chromogen DTNB is incorporated before incubation for 15 minutes at 25°C.
- the activity of the Phospholipase A2 enzyme with and without test or reference product is evaluated by measuring the absorbance of the reaction media at 413 nm. For each concentration tested, the modulation of the activity of the enzyme Phospholipase A2 by the product under test is calculated according to the following formula.
- Percentage of modulation of I ′ activity of I ′ enzyme Phospholipase AT 2 100 ⁇ DO 405 product To I ′ essay Or of reference ⁇ DO 405 sPLA 2 only / DO 405 sPLA 2 only .
- the peregrina extract according to the invention generates a slight inhibition stable of PLA2 from a dose of 0.1% but more preferably at 1 or 2%. This means that the peregrina extract according to the invention has the capacity to reduce the arachidonic cascade/inflammation cascade very upstream; this extract thus has a good soothing or relaxing potential on the skin.
- Endothelin is the most potent vasoconstrictor known in the human body.
- the decrease in endothelin is also known to create a vasodilating effect [ HIRATA Y. et al., 1988, Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells, Biochemical and Biophysical Research Communication 154: 3, p. 868-875 ,]
- HIRATA Y. et al., 2018, H2S Mediates the Vasodilator Effect of Endothelin-1 in the Cerebral Circulation. American Journal of Physiology. Heart and Circulatory Physiology 315, p. 1759-1764 ].
- the objective is to assay type 1 endothelin in human microvascular endothelial cells after exposure for 24 hours to the peregrina extract according to the invention.
- the values are from 63.14 pg/ml (with 5% of the extract according to the invention) to 101.06 pg/ml (with 0.1% of the extract according to the invention) , which shows very significant inhibitions from 0.1% of the extract according to the invention with approximately 25% inhibition of type 1 endothelin production and up to 53% inhibition with 5% of the extract according to the 'invention.
- Telomeres are DNA protective complexes located at the end of linear chromosomes that promote chromosomal stability. Telomere shortness in humans is emerging as a prognostic marker for disease risk and progression, and premature mortality in many types of cancers, including breast, prostate, colon, bladder , head and neck, lung and kidney cells [ ORNISH D., 2008, Increased Telomerase Activity and Comprehensive Lifestyle Changes: a Pilot Study, Lancet Oncology 9, p. 1048-1057 ]. Telomere shortening is counteracted by the cellular enzyme telomerase.
- the objective of the study is to evaluate the effect of the compound named "Extract peregrina according to the invention” on telomerase activity in a model composed of adult human keratinocytes at a low level of passage in monolayer culture.
- Incubation protocol The cells were incubated for 24 hours in the absence (control) or in the presence of reference product or of increasing concentrations of test compounds such as the peregrina extract according to the invention at: 0.5; 1 and 5% (v/v).
- the peregrina extract according to the invention is diluted directly in the incubation medium to reach the different concentrations described above.
- the peregrina extract according to the invention tested at 0.5% and 1% (v/v), did not significantly modulate the activity of telomerase compared with “Control”. Tested at 5% (v/v), the peregrina extract according to the invention significantly increased the activity of telomerase by 18.9% (p ⁇ 0.001), in comparison with “Control”. The reference product, called “FK228”, tested at 100 ng/ml, significantly increased telomerase activity by 28.0% (p ⁇ 0.01). This result was expected and validates the experiment. The results of stimulation of telomerase activity are given below. [Tables7] Extract strength Cell growth versus control (%) Telomerase activity versus control (%) Peregrina extract according to the invention 5.00% +5.8 +18.90 1.00% That. -2.2 +4.00 0.50% -2.6 +2.30
- the peregrina extract according to the invention tested at 0.5% and 1% (v/v), did not significantly modulate the activity of telomerase compared to “Control”.
- Tested at 5% (v/v) the peregrina extract according to the invention significantly increased the activity of telomerase by 18.9% (p ⁇ 0.001) in comparison with “Control”.
- the extract according to the invention acts directly on this enzymatic pathway which builds protective telomere at the ends of the chromosomes and slows down the natural aging of the genetic material.
- the extract according to the invention therefore makes it possible to produce an anti-aging effect on the chromosomes.
- Examples 2 to 7 make it possible to demonstrate that the peregrina extract according to the invention has anti-ageing, anti-stress and relaxing properties which demonstrates a profile of a good skin protector.
- a buffered solution of Tyrosinase reacts with a 2.5 mM L Tyrosine substrate for 60 minutes at 23°C and transforms it to form a colored compound.
- the maximum activity of Tyrosinase can thus be evaluated by measuring the absorbance at 475 nm.
- the peregrina extract according to the invention or the "Hydroquinone" reference product are brought into contact with the Tyrosinase solution at the same time as the enzyme substrate for 60 minutes at 23° C., the substrate transformed by the enzyme is naturally colored.
- Tyrosinase activity in the presence of the active ingredient is then evaluated by measuring the absorbance at 475 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the maximum activity of Tyrosinase in the absence of active ingredient, that is to say only in the presence of the substrate of the enzyme (L Tyrosine) .
- a Tyrosinase enzyme solution is incubated in its L Tyrosine substrate for 60 minutes in the absence (control) or presence of the reference product, or of increasing concentrations of the peregrina extract according to the invention/concentrations; 2%; 1%; 0.1% (V/V).
- the activity of the Tyrosinase enzyme with and without test or reference product was evaluated by measuring the absorbance of the reaction media at 475 nm.
- the peregrina extract according to the invention is capable of lowering the basal activity rate of tyrosinase, which makes it possible to indicate that this extract has the capacity to increase one of the natural protections of the skin, the protection against ultraviolet rays.
- the objective of this study on human cell cultures is to bring together all the data used, as well as the results obtained, for carrying out the melanin modulation test on human melanocytes after exposure for 5 days to the peregrina extract. according to the invention.
- a viability cut-off value of 70% relative to the negative control value is used to classify the substances tested as cytotoxic or non-cytotoxic.
- a "non-cytotoxic” classification is given on the in vitro results for a viability > 70% and a "cytotoxic” classification for a viability ⁇ 70%.
- the peregrina extract according to the invention inhibits the production of melanin in cellulo , which gives it a protective property for the skin. This inhibition also shows a relaxing effect on the melanocytes because the basal rate is lower than the control (absence of extract according to the invention in the culture medium); it is recalled that the production of melanin is a response to cellular stress.
- the peregrina extract according to the invention demonstrates the ability to prevent aging spots.
- Moringa oleifera extract contains less than 1% DFF while Moringa peregrina extract contains more than 50%.
- Example 11 Comparative test with Moringa oleifera for collagenase in tubo test
- the objective of this study is to evaluate the modulation of the inhibitory activity of Metalloproteases by the peregrina extract according to the invention in an acellular in vitro model using a type I collagenase and a hyaluronidase, a complex of substrate and a chromophore, Ninhydrin.
- a buffered solution of Collagenase type I and hyaluronidase reacts with a specific substrate complex and converts it to form a compound capable of activating a chromophore by incubation at 80°C for 15 min.
- the collagenase and hyaluronidase activities can thus be evaluated by measuring the absorbance at 565 nm.
- the sample is brought into contact with the solution of Collagenase and Hyaluronidase at the same time as the substrate complex of the enzymes at 37° C. for 5 minutes.
- the substrate transformed by the enzymes is capable of activating the chromophore by incubation at 80° C. for 15 minutes.
- the Collagenase and Hyaluronidase activity in the presence/absence of the sample is then evaluated by measuring the absorbance at 565 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the activity of Collagenase and Hyaluronidase in the absence of active ingredient, that is to say only in the presence of the substrate of the enzyme.
- a solution of collagenase type I and hyaluronidase enzymes is incubated in its substrate, for 5 minutes, in the absence or presence of the peregrina extract according to the invention tested.
- the solutions are then brought into contact with the chromogen, Ninhydrin, before incubation for 15 minutes at 80°C.
- the activity of the Collagenase and Hyaluronidase enzymes with and without test or reference product was evaluated by measuring the absorbance of the reaction media at 565 nm. For each concentration tested, the modulation of the activity of the Collagenase and Hyaluronidase enzymes by the product under test is calculated according to the following formula.
- the peregrina extract according to the invention generates a strong inhibition of Metalloproteases (Collagenase/Hyaluronidase). It is capable of inhibiting these Metalloproteases by 88% from a concentration of 0.1% and has a good potential to protect with high efficiency the extra-cellular matrix of the skin and, by this inhibition, it shows an anti-aging effect.
- Metalloproteases Collagenase/Hyaluronidase
- the extract according to the Pierre Fabre patent shows a slight inhibitory action on the collagenase activity in inverse dose-dependence with a peak inhibition of 42% all concentrations combined against a peak inhibition of 100% for the extract peregrina according to the invention.
- Example 12 Comparative tests for anti-stress activity (by inhibition of PLA2).
- the objective of this study is to evaluate the modulation of the anti-inflammatory activity of the enzyme phospholipase A2 by one or more samples in an acellular In Vitro model using the "SPLA2 (type V) Inhibitor” analysis kit. Screening Assay Kit”.
- a buffered solution of Phospholipase A2 reacts with a specific substrate, diheptanoyl thio-PC, and converts it to form a compound which binds to a chromogen, DTNB under stirring at room temperature.
- the activity of phospholipase A2 can thus be evaluated by measuring the absorbance at 413 nm.
- the products “ Peregrina extract according to the invention” or the inhibitor reference product “Thioetheramide-PC” are brought into contact with the solution of Phospholipase A2 at the same time as the substrate of the enzyme.
- the substrate transformed by the enzyme is stained using the chromogen DTNB by stirring at room temperature.
- the activity of Phospholipase A2 in the presence/absence of the product “ Peregrina extract according to the invention” or of the reference product is then evaluated by measuring the absorbance at 413 nm.
- the modulation of this activity is expressed as a percentage of inhibition or activation of the activity of Phospholipase A2 in the absence of active ingredient, that is to say only in the presence of the substrate of the enzyme (diheptanoyl thio- pc).
- the “Thioetheramide-PC” inhibitor at a concentration of 1mg in 100 ⁇ l is the reference product (active control) in this study, the latter inhibiting the activity of PLA2 by 93%, which validates the test.
- the activity of the Phospholipase A2 enzyme with and without test or reference product was evaluated by measuring the absorbance of the reaction media at 413 nm.
- the extract shows no activity. On dilution, an activity appears but the lack of dose-dependent effect does not make it possible to validate a specific and reliable action of the extract on the inhibition of this enzyme.
- This extract shows a slight inhibitory action which does not reach the maximum observed at 1% with the peregrina extract according to the invention, namely 19% inhibition for the extract according to the invention against 10% inhibition at 1% for this extract.
- This extract does not show any inhibitory action on this enzyme.
- Example 13 Formulation of a make-up product
- Example 14 Formulation of a washing product
- Example 15 formulation of a care product (anti-ageing anti-stress cream)
- Example 16 oral formulation for nutricosmetics
- a 1 g tablet for soothing/anti-stress activity comprises: 3% dry extract according to the invention (containing 0.6% of 2,5-diformylfuran on an inulin support) + 47% of calcium carbonate containing 200 IU of vitamin D + 25% magnesium gluconate + 22% inulin + 3% magnesium stearate.
- Example 17 Toxicological tests of the peregrina extract according to the invention
- the cytotoxicity test was performed on the S. typhimurium TA100 strain at concentrations of 5000, 1600, 500, 160 and 50 ⁇ g/plate, with and without S9-Mix.
- the peregrina extract according to example 1 can be considered as not exhibiting any mutagenic or pro-mutagenic activity.
- the principle of the test is based on the comparison of the cytotoxicity of the peregrina extract according to Example 1 in the presence and in the absence of a non-cytotoxic dose of UVA, on cells in culture. Cytotoxicity is evaluated by determining cell viability using a vital dye: neutral red, 24 hours after treatment with reference elements and M. peregrina extract with or without UVA irradiation.
- the cells used are mouse embryo fibroblasts of the Balb/c 3T3 line clone 31 (ATCC-CCL163).
- the positive control is a chlorpromazine solution (Number CAS: 69-09-0 ).
- the negative control is a diluent of the tested and reference extract (buffered saline solution +/- 1% solvent).
- the peregrina extract was tested at 8 concentrations on at least four culture wells per concentration studied, in the presence or absence of UVA.
- the fibroblasts were trypsinized and two 96-well culture plates were inoculated with 100 ⁇ l of a cell suspension at 2.10 5 cells/ml (ie 2.10 6 cells per well) in complete culture medium.
- the inoculated plates were incubated in an oven for 24 hours at 37° C., 5% CO 2 . At the end of the incubation, the semi-confluence of the cell layer was checked. The dilutions were prepared just before their deposit on the cells. The pH of the highest concentration was measured; it is between 6.5 and 8. The culture medium was removed, each well was gently rinsed beforehand with 150 ⁇ l of PBS maintained at room temperature before being treated with 100 ⁇ l of each dilution of the extract or reference . The culture plates were incubated in the dark for 1 hour plus or minus 5 minutes at 37° C. and 5% CO 2 .
- the irradiation was carried out using a BIO SUN solar irradiator (Vilber Lourmat RMX3W).
- BIO SUN is a system that controls UV irradiation using a programmable microprocessor. The system continuously monitors the emission of UV light. The irradiation stops automatically when the delivered energy is equal to the programmed energy.
- the spectral irradiation of the device under test was measured in the wavelength range 250 to 700 nanometers with a calibrated spectroradiometer. One of the 2 plates was irradiated with its cover at room temperature, and the other plate was protected from UVA rays and kept at room temperature for the duration of the irradiation.
- the treatment medium was aspirated and the cells were rinsed. Then without ⁇ l of complete culture medium were added slowly and the plates were incubated for 18 to 22 h at 37° C. and 5% CO 2 . The following day, the cell viability (growth, morphology, integrity of the monolayer) was evaluated by observations on a phase-contrast microscope.
- the culture medium was removed, each well was rinsed beforehand and maintained at ambient temperature before being treated with 100 ⁇ l of the staining solution. The plates were returned to the incubator for 3 hours under the same conditions. The staining solution was removed and the cells were rinsed, then the rinse solution was removed and 150 ⁇ l of desorption solution was added to each well. The plates were shaken until the crystals were completely dissolved. Absorbances were measured at 450 nm.
- the sensitivity of the cells to UVA is checked approximately every 10 passages, by evaluating their viability after exposure to increasing doses of irradiation.
- Cells are cultured at the density used in the assay. They are irradiated the following day at a dose of 2.5 and 9 J/cm 2 and the cell viability is determined one day later using the NRU test.
- the cells meet the quality criteria if their viability after irradiation at 5 J/cm2 UVA is greater than or equal to 80% of the viability controls kept in the dark: at the highest dose of 9 J/cm2 UVA, the viability must be at least equal to 50% of that of the controls kept in the dark.
- the negative control has an absorbance greater than or equal to 0.4.
- Chlorpromazine a positive control, has an IC 50 of between 0.1 and 2 ⁇ g/ml in the presence of UVA and between 7 and 90 ⁇ g/ml in the absence of UVA.
- This in vitro study is based on the evaluation of the cytotoxicity of the extract of peregrina cake by determining the concentration resulting in 50% cell death (CI 50 ) on a cell monolayer using the salting-out technique of neutral red.
- the cells used are SIRC rabbit corneal fibroblasts (ATCC-CCL60) free of mycoplasma.
- the peregrina extract was diluted in saline at 25% and 50%.
- the fibroblasts were trypsinized and two 24-well culture plates were inoculated with 1 ml of a cell suspension at 2.10 5 cells/ml in complete culture medium.
- the inoculated plates were incubated in an oven overnight at 37° C., 5% CO 2 .
- the staining solution was prepared at 0.5 mg/ml in complete culture medium.
- the culture medium was eliminated, 1 ml of the coloring solution was deposited in each well.
- the plates were returned to the incubator at 37°C, 5% CO2 for 3 hours +/- 15 minutes.
- the coloring solution was removed and replaced with 1 ml of complete culture medium per well.
- the plates were kept at room temperature for at least 30 minutes in order to stabilize the system before contact with the extract or the reference.
- Each well was rinsed with 2 ml of PBS, maintained at ambient temperature, then 500 ⁇ l of each dilution of peregrina or reference extract were deposited in contact with the cell layer.
- the contact time was 60 seconds (30 seconds for the positive control).
- the treatment was carried out well by well with triggering of the stopwatch at the time of deposit of the peregrina extract or the reference.
- the plate was manually agitated throughout the treatment. After 55 seconds (or 25 seconds for the positive control, the dilution was sucked.
- the concentration of the peregrina extract giving 50% cell death was evaluated at >50%.
- the percentage of cell death at 50% peregrina extract was evaluated at 17%.
- the purpose of this study is to assess the degree of cutaneous compatibility of the peregrina extract by patch test, carried out on the antero-external face of the arm for 48 hours; and generally to assess the ability of the peregrina extract to maintain the skin in good condition.
- 10 healthy volunteers, female or male aged 18 to 65, with neither dry nor sensitive skin and free of any dermatological lesion on the treatment area were to be included in the study.
- the skin compatibility of the peregrina extract prepared in the form of a lotion with 5% of the peregrina extract according to example 1 and 95% of a Propanediol/Sorbitol mixture, was evaluated 48 hours after the initial application between 30 40 minutes after dressing removal.
- MII average irritation index
- MII Average Irritation Index
- Example 18 Evaluation by measuring the Transepidermal Water Loss (PIE) on the skin barrier and its acceptability after use over a period of 21 days
- PIE Transepidermal Water Loss
- the product studied in this study is the care product in the form of a cream of Example 15. This product is applied morning and evening to the clean face, massaging delicately, avoiding the eye contour. Measurements are taken at cheek level.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
- Extrakt aus den Samen von Moringa peregrina, dadurch gekennzeichnet, dass er durch Fest-Flüssig-Extraktion des Presskuchens aus den nicht geschälten Samen, unter Rühren, in einem Anteil von etwa 25 Gew.-%. des Feststoffs, bezogen auf das Gesamtgewicht, durchgeführt in einem überwiegend alkoholischen Lösemittel, wobei der Alkohol ausgewählt ist aus Ethanol oder Methanol mit gegebenenfalls einem Polyol oder subkritischem Wasser als Co-Lösemittel, wobei der Alkoholanteil zwischen 70 und 100 Gew.-%, bezogen auf das Gesamtgewicht des Lösemittels, liegt, bei einer Temperatur zwischen 16 und 30°C für eine Dauer von etwa 2 Stunden, und durch Trennung der flüssigen und festen Phasen, um die feste Phase zu entfernen, erhalten ist, um einen flüssigen Extrakt aus Samen von Moringa peregrina zu gewinnen, wobei der Extrakt reich an der Verbindung 2,5-Diformylfuran ist.
- Extrakt gemäß Anspruch 1, dadurch gekennzeichnet, dass der erhaltene flüssige Extrakt getrocknet ist, um einen trocknen Extrakt aus dem Presskuchen der Samen von Moringa peregrina zu erhalten, der mehr als 50 Gew.-%, bezogen auf das Gesamtgewicht des Trockenmaterials, 2,5-Diformylfuran umfasst.
- Verfahren zur Gewinnung eines Extrakts aus den Samen von Moringa peregrina gemäß einem der Ansprüche 1 bis 2, dadurch gekennzeichnet, dass es die folgenden Schritte umfasst:a) Sammeln und Trocknen von ungeschälten Samen von Moringa peregrina, um einen inneren Feuchtigkeitsgehalt von weniger als 8 % zu erhalten;b) Pressung der getrockneten Samen, sodass sich das Öl vom Rest der Samen trennt, um den Presskuchen zu erhalten,c) Mahlen des in Schritt b) erhaltenen Presskuchens,d) Dispersion des in Schritt c) erhaltenen Mahlguts in einem Anteil von etwa 25 Gew.-% des Feststoffs, bezogen auf das Gesamtgewicht, durchgeführt in einem überwiegend alkoholischen Lösemittel, wobei der Alkohol ausgewählt ist aus Ethanol oder Methanol mit gegebenenfalls einem Polyol oder subkritischen Wasser als Co-Lösemittel, wobei der Alkoholanteil zwischen 70 und 100 Gew.-%, bezogen auf das Gesamtgewicht des Lösemittels, liegt,e) Durchführung einer Fest-Flüssig-Extraktion unter Rühren bei einer Temperatur zwischen 16 und 30°C während einer Dauer von etwa 2 Stunden,f) Trennung der flüssigen und festen Phasen, um die feste Phase zu entfernen und um einen flüssigen Extrakt aus Presskuchen von Moringa peregrina zu gewinnen, undg) gegebenenfalls, wenn der Alkohol Ethanol ist, Trocknung des erhaltenen flüssigen Extrakts von Moringa peregrina, um einen festen Extrakt von Moringa peregrina zu erhalten.
- Verfahren gemäß Anspruch 3, dadurch gekennzeichnet, dass das überwiegend alkoholische Lösemittel das reine Lösemittel Ethanol 96° ist.
- Verfahren gemäß Anspruch 3, dadurch gekennzeichnet, dass der erhaltene flüssige Extrakt von Moringa peregrina durch Destillation, Mikrofiltration, Ultrafiltration und/oder Nanofiltration gereinigt wird, um den Extrakt an 2,5-Diformylfuran im Vergleich zu den ebenfalls extrahierten organischen Stoffen zu konzentrieren.
- Kosmetische oder nutrikosmetische Zusammensetzung, dadurch gekennzeichnet, dass sie als Wirkstoff eine wirksame Menge eines Extrakts aus Samen von Moringa peregrina gemäß einem der Ansprüche 1 bis 2 und einen physiologisch annehmbaren Hilfsstoff umfasst.
- Zusammensetzung gemäß Anspruch 6, dadurch gekennzeichnet, dass sie eine kosmetische Zusammensetzung ist, die formuliert ist, um topisch auf die Haut aufgetragen zu werden, und dass der Extrakt aus Samen von Moringa peregrina in der Zusammensetzung in einer Konzentration von 0,002 bis 20 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung, vorzugsweise von 0,01 bis 10 Gew.-%, vorliegt.
- Zusammensetzung gemäß Anspruch 6, dadurch gekennzeichnet, dass sie eine nutrikosmetische Zusammensetzung ist, die formuliert ist, um eingenommen zu werden, und dass der Extrakt aus Samen von Moringa peregrina in der Zusammensetzung in einer Konzentration von 0,01 bis 100 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung, vorliegt.
- Kosmetische oder nutrikosmetische Verwendung einer Zusammensetzung gemäß einem der Ansprüche 6 bis 8, um das Aussehen der Haut, der Schleimhäute oder der Anhangsgebilde zu verbessern, die Haut zu entspannen, zu beruhigen und zu entstressen und den Hautalterungserscheinungen und/oder der Fotoalterung vorzubeugen und/oder zu bekämpfen und zur Vorbeugung von Altersflecken.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2005429A FR3110419B1 (fr) | 2020-05-21 | 2020-05-21 | Extrait de graines de Moringa peregrina riche en 2,5-diformylfuran, son procédé d’obtention et son utilisation dans des compositions cosmétiques |
FR2102686 | 2021-03-17 | ||
PCT/EP2021/063690 WO2021234159A1 (fr) | 2020-05-21 | 2021-05-21 | Extrait de graines de moringa peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3980123A1 EP3980123A1 (de) | 2022-04-13 |
EP3980123B1 true EP3980123B1 (de) | 2023-07-05 |
EP3980123B8 EP3980123B8 (de) | 2023-09-20 |
Family
ID=76159430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21728208.6A Active EP3980123B8 (de) | 2020-05-21 | 2021-05-21 | An 2,5-diformylfuran reiches moringa-peregrina-samenextrakt, verfahren zu seiner herstellung und seine verwendung bei kosmetischen zusammensetzungen |
Country Status (15)
Country | Link |
---|---|
US (1) | US11717476B2 (de) |
EP (1) | EP3980123B8 (de) |
JP (1) | JP7412811B2 (de) |
KR (1) | KR102563369B1 (de) |
CN (1) | CN114502139B (de) |
AU (1) | AU2021274894B2 (de) |
BR (1) | BR112022020666A2 (de) |
CA (1) | CA3173694C (de) |
ES (1) | ES2960038T3 (de) |
IL (1) | IL290645B2 (de) |
JO (1) | JOP20220032A1 (de) |
PL (1) | PL3980123T3 (de) |
PT (1) | PT3980123T (de) |
WO (1) | WO2021234159A1 (de) |
ZA (1) | ZA202213542B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4321150A1 (de) * | 2022-08-08 | 2024-02-14 | AlUla Peregrina Trading Company | Kosmetische topische zusammensetzung zur verbesserung der kapillardichte mit mindestens einem öligen extrakt von moringa-peregrina-samen als wirkstoff, verfahren zur herstellung der zusammensetzung und verfahren zur kosmetischen behandlung von haaren |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776519B1 (fr) | 1998-03-24 | 2000-11-17 | Serobiologiques Lab Sa | Utilisation d'au moins un extrait proteique de graines de plantes du genre moringa et composition cosmetique et/ou pharmaceutique correspondante |
FR2825267B1 (fr) | 2001-05-29 | 2009-08-28 | Philippe Jean Louis Thurot | Compositions pour l'hygiene buccale ou corporelle ou la proprete ou la sante comprenant des graines ou un broyat de graines ou un extrait de graines du genre moringa |
FR2946879B1 (fr) * | 2009-06-22 | 2012-05-18 | Fabre Pierre Dermo Cosmetique | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques. |
KR101915660B1 (ko) | 2012-01-31 | 2018-11-06 | (주)아모레퍼시픽 | 모링가씨 추출물을 함유하는 피부 외용제 조성물 |
FR3076460B1 (fr) | 2018-01-09 | 2020-11-13 | Basf Beauty Care Solutions France Sas | Utilisation cosmetique d'un extrait proteique des graines de moringa oleifera |
KR102140769B1 (ko) * | 2018-07-19 | 2020-08-03 | 주식회사 바이오스탠다드 | 모링가 추출물을 함유하는 미세먼지 흡착 또는 제거용 조성물 |
KR102111272B1 (ko) * | 2019-05-14 | 2020-05-15 | 권태동 | 초임계 트랜스에스테르화 모링가 오일 및 모링가 종자박 아임계수 추출물의 수득방법과, 그 방법에 의해 획득된 초임계 트랜스에스테르화 모링가 오일 및 모링가 종자박 아임계수 추출물을 유효성분으로 한 화장료 유화 조성물 |
-
2021
- 2021-05-21 JP JP2022571149A patent/JP7412811B2/ja active Active
- 2021-05-21 US US17/633,380 patent/US11717476B2/en active Active
- 2021-05-21 KR KR1020227040703A patent/KR102563369B1/ko active IP Right Grant
- 2021-05-21 ES ES21728208T patent/ES2960038T3/es active Active
- 2021-05-21 AU AU2021274894A patent/AU2021274894B2/en active Active
- 2021-05-21 JO JOP/2022/0032A patent/JOP20220032A1/ar unknown
- 2021-05-21 PL PL21728208.6T patent/PL3980123T3/pl unknown
- 2021-05-21 BR BR112022020666A patent/BR112022020666A2/pt active Search and Examination
- 2021-05-21 CA CA3173694A patent/CA3173694C/fr active Active
- 2021-05-21 WO PCT/EP2021/063690 patent/WO2021234159A1/fr active Application Filing
- 2021-05-21 PT PT217282086T patent/PT3980123T/pt unknown
- 2021-05-21 CN CN202180005682.3A patent/CN114502139B/zh active Active
- 2021-05-21 EP EP21728208.6A patent/EP3980123B8/de active Active
-
2022
- 2022-02-15 IL IL290645A patent/IL290645B2/en unknown
- 2022-12-14 ZA ZA2022/13542A patent/ZA202213542B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL290645B1 (en) | 2023-03-01 |
IL290645A (en) | 2022-04-01 |
ES2960038T3 (es) | 2024-02-29 |
WO2021234159A1 (fr) | 2021-11-25 |
KR20230002938A (ko) | 2023-01-05 |
EP3980123A1 (de) | 2022-04-13 |
JOP20220032A1 (ar) | 2023-01-30 |
IL290645B2 (en) | 2023-07-01 |
JP7412811B2 (ja) | 2024-01-15 |
PL3980123T3 (pl) | 2023-12-27 |
EP3980123B8 (de) | 2023-09-20 |
PT3980123T (pt) | 2023-09-29 |
AU2021274894B2 (en) | 2022-10-27 |
CN114502139A (zh) | 2022-05-13 |
CA3173694C (fr) | 2023-09-05 |
BR112022020666A2 (pt) | 2022-11-29 |
JP2023518124A (ja) | 2023-04-27 |
US11717476B2 (en) | 2023-08-08 |
CA3173694A1 (fr) | 2021-11-25 |
ZA202213542B (en) | 2024-02-28 |
CN114502139B (zh) | 2023-04-25 |
AU2021274894A1 (en) | 2022-10-06 |
KR102563369B1 (ko) | 2023-08-03 |
US20230133310A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2049074B1 (de) | Nicht-therapeutische Verwendung eines Reisprotein-Hydrolysats als pigmentierender Wirkstoff | |
EP3980124B1 (de) | Extrakt aus moringa-peregrina-samenkuchen, verfahren zu seiner herstellung und seine verwendung in kosmetischen oder nutrikosmetischen zusammensetzungen | |
FR3065172A1 (fr) | Preparation cosmetique contenant un extrait de truffe blanche et procede cosmetique associe | |
EP3727603B1 (de) | Kapokbaumblütenextrakt und kosmetische, pharmazeutische oder dermatologische zusammensetzungen damit | |
EP3113850B1 (de) | Hautaufhellende kosmetikzusammensetzung | |
FR3106754A1 (fr) | Procede d’obtention d’un extrait aqueux de lavande, compositions comprenant un tel extrait et leurs utilisations cosmetiques | |
WO2012172199A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
EP3980123B1 (de) | An 2,5-diformylfuran reiches moringa-peregrina-samenextrakt, verfahren zu seiner herstellung und seine verwendung bei kosmetischen zusammensetzungen | |
FR3055214B1 (fr) | Composition cosmetique eclaircissante | |
EP3871658A1 (de) | Wirkstoff, der ein extrakt aus schwarzem hafer und ein extrakt aus kaktusfeigen enthält, und kosmetische anwendungen insbesondere gegen haarergrauen | |
OA21067A (fr) | Extrait de graines de Moringa Peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques. | |
FR3110419A1 (fr) | Extrait de graines de Moringa peregrina riche en 2,5-diformylfuran, son procédé d’obtention et son utilisation dans des compositions cosmétiques | |
FR3066118A1 (fr) | Extrait de sechium edule pour lutter contre les effets nocifs des rayonnements ultraviolets | |
EP2699227A2 (de) | Pflanzenextraktkomplex zum schutz der haut | |
OA21068A (fr) | Extrait du tourteau des graines de Moringa Peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques. | |
FR3110346A1 (fr) | Extrait du tourteau des graines de Moringa peregrina, son procédé d’obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques | |
BR122024003219A2 (pt) | Extrato de semente de moringa peregrina, composição cosmética ou nutricosmética compreendendo o mesmo e seu uso | |
EP2811977A2 (de) | Verwendung eines apfelbaumblattextraktes in einer kosmetischen hautfestigenden zusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220104 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref document number: 602021003300 Country of ref document: DE Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0017000000 Ipc: A61K0036185000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61Q 19/10 20060101ALI20230126BHEP Ipc: A61Q 19/08 20060101ALI20230126BHEP Ipc: A61Q 1/02 20060101ALI20230126BHEP Ipc: A61K 8/9789 20170101ALI20230126BHEP Ipc: A61K 8/49 20060101ALI20230126BHEP Ipc: A61Q 19/00 20060101ALI20230126BHEP Ipc: A61P 17/00 20060101ALI20230126BHEP Ipc: A61K 36/185 20060101AFI20230126BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20230214 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1584204 Country of ref document: AT Kind code of ref document: T Effective date: 20230715 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021003300 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
GRAT | Correction requested after decision to grant or after decision to maintain patent in amended form |
Free format text: ORIGINAL CODE: EPIDOSNCDEC |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: RECTIFICATION B8 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602021003300 Country of ref document: DE Owner name: AGENCE FRANCAISE POUR LE DEVELOPPEMENT D'AL UL, FR Free format text: FORMER OWNER: AGENCE FRANCAISE POUR LE DEVELOPPEMENT D'ALULA, PARIS, FR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PK Free format text: RECTIFICATIONS |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3980123 Country of ref document: PT Date of ref document: 20230929 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20230926 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20230705 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231006 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231105 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231006 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2960038 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240229 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602021003300 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230705 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240423 Year of fee payment: 4 |
|
26N | No opposition filed |
Effective date: 20240408 |